World Anti-Microbial Resistance Congress

🦠 Superbugs ‘could kill 39m people by 2050’ amid rising drug resistance – new research released this week has announced – and there are calls for new antibiotics to be developed to save millions of lives. 💊 But should we really be hyperfocused on drug screening new antibiotics? Or should we look beyond? Earlier this month, at the World Anti-Microbial Resistance Congress in Philadelphia, a cross-section of #antibiofilm thought-leaders came together to discuss the incredible ubiquity of bacterial biofilms (80% of longstanding bacterial problems) and how they are an engine room for #AntimicrobialResistance. Panelists Maud Eijkenboom (Lixa), Steve St. Onge (Clarametyx Biosciences) and Carl Genberg (N8 Medical) shared deeply personal #AMR stories, underlying the drive to pioneer novel antibiofilm technologies and breaking ranks with the predominant antibiotic focus. The 3 companies described the different antibiofilm mechanisms of action, their clinical progress and the hurdles they faced by a funding and regulatory system designed for an outdated “planktonic bacteria” concept. The panel was met by a full room of engaged audience members, showing the support from clinicians and scientists for change. Much kudos to the inimitable Ted Buckley, PhD (Shionogi & Co., Ltd), who expertly managed the lively interactions in that room. One key message: “The post antibiotic era might just be a transition towards understanding that bacterial colonies need to be treated differently from free-floating bacteria. A transition towards clinical flexibility with a multipronged approach of antibiofilms, resistance breakers, antibiotics and others. ” 👏 A big thank you to the World AMR Congress organizers for facilitating this dialogue and to everyone that came along and took part in the discussion. 

At the recent World Anti-Microbial Resistance Congress, Mark Williams, associate director, FasterCures, spoke on a panel discussing how we might overcome the continuing market challenges around antibiotic development to counter the growing threat of #antimicrobialresistance (AMR). Mark highlighted the need for implementing financial mechanisms, like pull incentives, to support the antibiotic development pipeline, and how we could create an environment to draw in desperately needed private capital with the models proposed in the FasterCures report in collaboration with the Milken Institute’s Financial Innovations Labs®. Read the report here: https://lnkd.in/efqnMJZj

Excited to share my blog post in PLOS which highlights the critical role of #DecentralizedDiagnostics in fighting #AMR, with all eyes on the United Nations HLM this month. Please read and let us know if there are ways Molbio Diagnostics can work with you to support #HealthForAll goals. World Anti-Microbial Resistance Congress

Have we been distracted, ignoring, or minimizing the silent threats to our healthcare facilities? I'm speaking about the elephant in the room aka C.auris and other deadly MDROs. In this newsletter, I share my key takeaways from two amazing presentations at the Disease Prevention & Control Summit and World Anti-Microbial Resistance Congress last week. In my articles on Infection Control Today® , I share Julie Paoline, MA, CPHA, CIC, FAPIC's and Sean Brown, CIC, CPHQ's insights on these two topics. Check them out! ⬇ Happy Friday! #infectionprevention #infectioncontrol #mdro

🌍 Last week, FAIRR participated in the World Anti-Microbial Resistance Congress which brought together global stakeholders to discuss strategies and innovations around #AntimicrobialResistance. 💊 During a fireside chat, Emma Berntman, PhD, FAIRR’s Senior Engagement Specialist, and Maria Larsson Ortino, Senior Global ESG Manager at Legal & General Investment Management (LGIM), explored the role investors can play in mitigating the development of #AMR. ✍️ They discussed the value of instigating stewardship dialogues with companies and policymakers, spotlighting concrete examples such as the latest investor statement convened by the Investor Action on Antimicrobial Resistance (IAAMR) initiative and the investor guide on AMR co-authored by FAIRR and MSCI Sustainability Institute. More broadly, participants of the Congress reaffirmed the need for increased funding of new antimicrobials and highlighted the opportunities #ArtificialIntelligence can provide, as well as the continued need for cross-disciplinary collaboration. While it was encouraging to see more discussions on the environmental aspect of antimicrobial contamination of #wastewater than in previous years, agricultural use of antibiotics was not covered as extensively - despite nearly 75% of global antibiotic use occuring in animal agriculture. Learn more about FAIRR’s Antibiotics & Health workstream ➡️ https://lnkd.in/eh7xM8br

Last week we wrapped up our 10th edition of World Anti-Microbial Resistance Congress and Disease Prevention & Control Summit. Thank you to everyone who attended in support of the global fight against AMR and future pandemics, and hope we continue these crucial conversations beyond next week's High-level UN meeting. I'll now be transitioning from AMR to the rare disease space for our World Orphan Drug Congress USA. Please feel free to connect if interested in any speaking opportunites.

Just last week, I had the honor of participating in the World Anti-Microbial Resistance Congress held in Philadelphia. My mind is still buzzing with the wealth of knowledge that was shared, but one presentation stands out. Catherine BERTRAND-FERRANDIS from OLYLO Company, during her insightful talk on “How can we protect from infodemic impacts? A Onde Health perspective on the information environment”, threw light on the complex interplay between information overload and its influence on public health. The in-depth discussion on Infodemic Management was indeed an eye-opener. It demonstrated how crucial authentic and accurate information is to reach the public, especially in the era of fake news and misinformation. Quality information is not just a pursuit of knowledge, it is a lifesaver. The need for effective strategies to fight false information is urgent, now more than ever. What are your thoughts on managing the infodemic and ensuring the public receives reliable, accurate information? #InfodemicManagement #PublicHealth #FightMisinformation #WorldAMRcongress #HealthInnovation

Beyond the Standards: Dr. Tracy Rivett (Young), PhD. Delivers Insightful Presentation on Biofilms and Antimicrobial Resistance at World Anti-Microbial Resistance Congress We’re proud to announce that Dr. Tracy Rivett (Young), PhD., Biofilm Expert at BluTest Laboratories — A Tentamus Company, recently delivered an impactful presentation at the World AMR Congress! Dr. Rivett's insights are driving the conversation forward on how we can better combat AMR through innovative research and testing. 🌍🦠 Read our latest article to learn more about our expert's presentation and the future of biofilm research in antimicrobial efficacy testing here https://lnkd.in/eH-3VHs6 #AMR #Biofilms #AntimicrobialResistance #InnovationInScience #BiofilmResearch #WorldAMRCongress #Tentamus

During this Sepsis Awareness Month, I was honored to meet with Thomas Heymann CEO of Sepsis Alliance and discuss how ASP pharmacists, leading antimicrobial stewardship initiatives across acute care community hospitals, can play a pivotal role in patient advocacy and the fight against AMR. Thank you for the inspiring ideas, Thomas! I look forward to the #opportunity to speak Sepsis Alliance in the future on the important topic of operationalizing clinical wisdom in the context of sepsis. Day 2 of the World Anti-Microbial Resistance Congress highlighted diagnostic stewardship as the key focus. Learning from researchers on a variety of available methods—AmpC detection kits, rapid urine culture tests in UK, synthetic anti-infectives in Australia, and biofire multiplex PCR tests bioMérieux —showcased the cutting-edge advancements in this space. The discussions around antibiofilms, breakthrough biological therapeutics in surgery, trauma care, and metagenomics were truly enlightening. Special thanks to John Alter (AMR Action Fund) for facilitating a fantastic conversation on leveraging partnerships for antimicrobial developments. I also want to extend my gratitude to Bala Subramanian, Yann Ferrisse (Global Antibiotic R&D Partnership (GARDP) and Richard Snyder for engaging in insightful dialogue about the anticipated gaps in available therapeutics for hospitals globally, where antimicrobial stewardship pharmacists will need to provide critical answers in the face of limited options. It’s clear the call for research, patient advocacy, and novel antibiotic development is more urgent than ever. Taking a vacation from work to connect with leaders and attend the 2nd day of the World Anti-Microbial Resistance Congress may seem extreme, but I don’t regret a single moment! One thing was clear – clinicians are key to raising awareness and advocating for patient safety through dialogue on research and innovation in the #AMR space. #AMR #SepsisAwareness #AntimicrobialStewardship #PharmacyLeadership #PatientSafety #InnovationInHealthcare #Antibiotics #Stewardship

The Tentamus NA and Tentamus UK Team at World Anti-Microbial Resistance Congress last week in Philadelphia. Had a great event exhibiting with Tracy Rivett (Young), PhD., Daniel Yaxley, and Bradley Davis, representing Tentamus Group, Adamson Analytical Laboratories, BluTest Laboratories — A Tentamus Company, and AFL - Analytical Food Laboratories, INC. #Tentamus #LabsforLife #AMR